a16z Bio + Health #18: What will it take to cure diabetes?

from a16z Live · host Jorge Conde, Karen Jordan, Doug Melton, Vineeta Agarwala, Aaron Neinstein, Venkat Mocherla, Aaron Kowalski

An overview of diabetes Type 1 and Type 2 [2:58]Thinking beyond Type 1 and Type 2 [6:58]New treatment options: stem cells, continuous glucose monitoring [14:19]What's the timeline on stem cell therapies? [17:15]Therapies for controlling, rather than curing, diabetes [23:52]The current technology challenges to treating diabetes [29:52]The challenges in education and access [35:41]This is an excerpt from the a16z Bio show on Clubhouse, where we explore all the ways that biology is technology. To catch full episodes of the show, follow the a16z Club on Clubhouse.

Episode metadata supplied by the publisher feed · Published Sep 3, 2021

Embed this episode

Attribution link and audio player

What this episode covers

Nearly one in seven Americans has diabetes, but our understanding of the disease has long been limited to two types (Type 1 and Type 2) with a focus on glucose and insulin. But breakthroughs in insulin delivery, glucose monitoring, stem cell therapies, and other diabetes treatments are helping to debunk misconceptions of diabetes as a lifestyle disease and evolving the ways we fight it. So, what is the current landscape of treatments? And what more will it take to cure diabetes? The a16z Bio team talks to Doug Melton (Harvard Stem Cell Institute) and Aaron Kowalski (CEO of JDRF).